HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Clinical trials for HR POSITIVE/HER-2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR POSITIVE/HER-2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HR POSITIVE/HER-2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug targets Hard-to-Treat cancers with PIK3CA mutation
Disease control Recruiting nowThis early-phase study tests an experimental drug called CGT6297 in about 90 adults whose advanced solid tumors (including certain breast and endometrial cancers) have a specific genetic change called PIK3CA. The main goals are to find a safe dose and see if the drug can shrink o…
Matched conditions: HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
Simple blood test could predict breast cancer return
Knowledge-focused Recruiting nowThis study is looking at whether a simple blood test can find tiny bits of cancer DNA left in the body after breast cancer treatment. These leftover cells, called minimal residual disease (MRD), can sometimes cause the cancer to come back. The study will follow 900 breast cancer …
Matched conditions: HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Sponsor: Tempus AI • Aim: Knowledge-focused
Last updated Jun 22, 2026 11:58 UTC